FindTrial
Sign In

Real-world data analysis of nimotuzumab combined with chemotherapy as first-line treatment for advanced pancreatic cancer

Real-world data analysis of nimotuzumab combined with chemotherapy as first-line treatment for advanced pancreatic cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500095311
Enrollment
Unknown
Registered
2025-01-06
Start date
2025-01-06
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced pancreatic cancer

Interventions

Experimental group:Nimotuzumab combined with chemotherapy

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years old, including 18 years old and 75 years old; 2. ECOG PS score 0-2; 3. Advanced unresectable pancreatic cancer diagnosed by pathology; 4. At least one measurable lesion according to RECIST version 1.1 evaluation criteria; 5. First-line treatment with nimotuzumab combined with chemotherapy for at least 1 evaluation cycle.

Exclusion criteria

Exclusion criteria: Has a history of other malignancies (except cured carcinoma in situ of the cervix or basal cell carcinoma of the skin and other malignancies that have been cured for more than 5 years)

Design outcomes

Primary

MeasureTime frame
Median progression-free survival;—

Countries

China

Contacts

Public ContactMeiqin Yuan

Zhejiang Cancer Hospital

yuanmq@zjcc.org.cn+86 571 88122052

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026